Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;6(2):98-110.
doi: 10.1016/j.trecan.2020.01.007. Epub 2020 Feb 5.

TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines

Ashkan Shahbandi  1 , Hoang D Nguyen  1 , James G Jackson  2
Affiliations
Review

TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines

Ashkan Shahbandi et al. Trends Cancer. 2020 Feb.

Abstract

TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53 mutations and small cohorts that combined patients treated with drugs having very different mechanisms of action. When only studies of patients receiving the same treatment(s) were compared, they tended to agree. These analyses reveal a role for TP53 in response to different treatments as complex as its different biological activities. We discuss studies that have assessed the role of TP53 mutations in breast cancer treatment and limitations in interpreting reported results.

Keywords: TP53; breast cancer; chemotherapy; hormone therapy; survival; tamoxifen; tumor suppressors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Breast Cancer Patient Survival after Stratification for TP53 Status and Treatment.
Median survival was determined for patients from the METABRIC database, stratified by TP53 mutation status and treatment exposure. Studies that analyzed patients under similar treatment conditions are listed in adjacent captions. (A) All patients (P <0.0001). (B) All chemotherapy-treated patients (P = ns). (C) All patients who did not receive chemotherapy (P <0.0001). (D) All patients treated with chemotherapy + HRT (P <0.05). (E) All patients treated with chemotherapy alone (P <0.05). (F) All patients treated with HRT only (P <0.0001). (G) All patients who did not receive chemotherapy or HRT (P = ns). Abbreviations: HRT, hormonal therapies; mut, mutant; ns, not significant; OS, overall survival; WT, wild type. (See [,–,–,–91].)
See this image and copyright information in PMC

References

    1. TCGA-Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 - PMC - PubMed
    1. Kastenhuber ER and Lowe SW (2017) Putting p53 in context. Cell 170, 1062–1078 - PMC - PubMed
    1. Tonnessen-Murray C et al. (2016) The p53 protein: from cell regulation to cancer. In The p53 Protein: From Cell Regulation to Cancer (Lozano G and Levine AJ, eds), pp. 173–186, Cold Spring Harbor Laboratory Press
    1. Soussi T (2011) TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv. Cancer Res 110, 107–139 - PubMed
    1. Soussi T and Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1, 233–240 - PubMed

Publication types

MeSH terms

Substances